Search

As part of the accelerated development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant justification study of SCB-2019, a protein subunit vaccine candidate containing a stabilised trimeric form of the spike (S)-protein (S-Trimer) combined with two different adjuvants.

Congratulations to three outstanding The Kids Research Institute Australia researchers who have received second chance WA health funding designed to support researchers who have narrowly missed out on highly competitive national funding.

Almost one in five children across four remote Kimberley communities has some form of chronic lung disease, according to a new study co-designed and conducted in partnership with Aboriginal communities.

Two researchers focused on improving outcomes for children with chronic lung disease and averting suicide contagion and suicide clusters in young people have won prestigious Investigator Grants from the National Health and Medical Research Council.

Charlie, 6, has ended up in hospital twice with invasive Strep A infection over his short lifetime – the first time when just three years old.

The urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.

Hannah Peter Moore Richmond OAM BSc (Hons) GradDipClinEpi PhD MBBS MRCP(UK) FRACP Head, Infectious Diseases Research Head, Vaccine Trials Group 08

The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.

Cohort studies investigating respiratory disease pathogenesis aim to pair mechanistic investigations with longitudinal virus detection but are limited by the burden of methods tracking illness over time. In this study, we explored the utility of a purpose-built AERIAL TempTracker smartphone app to assess real-time data collection and adherence monitoring and overall burden to participants, while identifying symptomatic respiratory illnesses in two birth cohort studies.

Objective: To review systematically the rationale for choice and use of monoclonal antibody and anti-cytokine therapy in multisystem inflammatory syndrome in children.